Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Talanin (LINC02929)
- Target
- LINC02929
- Molecular classification
- Other (Possible lincRNA), Other (Possible protein-coding), Zinc finger family (if ZNF365 context considered)
01
Overview
Talanin (encoded by LOC124902436/ZNF365D transcript) is a gene product detected in humans, possibly arising by alternative splicing of the ZNF365 locus, with limited evidence for biological function or disease involvement. It is reported as associated with susceptibility to human uric acid nephrolithiasis but lacks characterization as a molecular target for therapeutic intervention. Database cross-annotation (BioGPS, GeneCards) describes talanin as protein-coding; however, the LINC02929 designation implies a non-coding RNA, and there are gaps or inconsistencies in functional annotation. No reported drug interactions, mechanisms, or biomarker status are available, indicating an incomplete or possibly erroneous entry for a therapeutic target. Annotation of LINC02929/talanin/LOC124902436 is inconsistent and does not align with standard molecular target criteria; its role (if any) in human biology or disease is speculative, not experimentally validated, and not linked to drug targeting pathways.
- Other names
- TalaninLOC124902436ZNF365D transcriptLong intergenic non-protein coding RNA 2929
02
Mechanism of action
None reported
03
Biological functions
Other (no clearly established function for LINC02929/talanin)Possible DNA binding (per ZNF365 family context)Possible genome stability (per ZNF365 family context)
04
Disease associations
Other (emerging evidence links talanin/ZNF365D transcript to susceptibility for uric acid nephrolithiasis, but not as a classical disease target)
Beyond the preview
Go deeper on Talanin (LINC02929).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Talanin (LINC02929).